# The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients

> **NCT01052311** · PHASE4 · TERMINATED · sponsor: **Sheba Medical Center** · enrollment: 8 (actual)

## Conditions studied

- Coronary Artery Disease
- Dyslipidemia

## Interventions

- **DRUG:** Tredaptive (1 g extended release niacin+ 20 mg laropiprant)
- **DRUG:** Placebo
- **DRUG:** Tredaptive

## Key facts

- **NCT ID:** NCT01052311
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The sponsor decided to withdraw study drug from market
- **Last updated:** 2016-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01052311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01052311, "The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01052311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*